An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus
Study identifier:H8O-MC-GWAN
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 3
Healthy volunteers
No
Study drug
exenatide
Sex
All
Actual Enrollment
275
Study type
Interventional
Age
30 Years - 75 Years
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Jul 2008
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Eli Lilly and Company
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Group A Exenatide injection 5mcg or 10 mcg, twice daily | Drug: exenatide subcutaneous injection, 5mcg or 10 mcg, twice daily Other Name: Byetta |
Contacts
Investigators
Principal Investigator
Chief Medical Officer
Eli Lilly and Company
